Identifying the targets of broadly neutralizing antibodies to HIV-1 and understanding how these antibodies develop remain important goals in the quest to rationally develop an HIV-1 vaccine. We previously identified a participant in the CAPRISA Acute Infection Cohort (CAP257) whose plasma neutralized 84% of heterologous viruses. In this study we showed that breadth in CAP257 was large... https://www.spidertattooz.com/OPI-GelColor-The-Color-That-Keeps-On-Giving-0-5-oz-HPJ07-p22791/